Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% sodium chloride solution Clear all
Terminated Phase 1Phase 2 Interventional

ST266 Versus Standard Care In Treating Partial Thickness Burns

NCT00886470
View directory record Official record
Conditions
Burns
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Los Angeles, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

NCT05229588
View directory record Official record
Conditions
Gastrointestinal Malignancies
Interventions
Lurbinectedin 4 MG Injection [Zepzelca]
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

NCT03821402
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
26
States / cities
Downey, California • Fountain Valley, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

NCT01843790
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
GCS-100, Placebo, Saline
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Genicular Nerve Block for Total Knee Arthroplasty

NCT03706313
View directory record Official record
Conditions
Post-operative Pain
Interventions
15mL 0.25% bupivacaine, Genicular nerve block, Saline
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 15, 2026, 1:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sorting of Oral Sensations

NCT02390180
View directory record Official record
Conditions
Taste Qualities, Primary Tastes
Interventions
Tasting solutions
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional

Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries

NCT02980835
View directory record Official record
Conditions
Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Interventions
Normal Saline, Ropivacaine, Epinephrine, Dexamethasone
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

NCT02427191
View directory record Official record
Conditions
Fasciitis, Plantar
Interventions
AmnioFix® Injectable, Saline Injection
Other · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 79 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Fresno, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated Phase 2 Interventional Results available

Tranexamic Acid and Thromboelastography During Cesarean Delivery

NCT02026297
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Tranexamic Acid, Placebo; Normal Saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy

NCT01976585
View directory record Official record
Conditions
Low-Grade B-cell Lymphoma
Interventions
rhuFlt3L/CDX-301, Poly-ICLC
Drug
Lead sponsor
Joshua Brody
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 4 Interventional Results available

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

NCT06112353
View directory record Official record
Conditions
Intestinal Disease
Interventions
Neostigmine Injectable Solution, Sugammadex injection
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prevention of GBS Colonization Via Immunity

NCT00128219
View directory record Official record
Conditions
Beta Haemolytic Streptococcal Infection
Interventions
GBS III-TT, Tetanus and diptheria toxoids vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
3
States / cities
Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

NCT03556007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 1:21 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Sphenopalatine Ganglion Block and Cold Induced Headaches

NCT06310200
View directory record Official record
Conditions
Cold Induced Headache, Brain Freeze, Cold Induced Cephalgia, Headache
Interventions
Lidocaine Topical 4% Topical Solution, Bitrex, normal saline
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886
View directory record Official record
Conditions
Shock, Cardiogenic
Interventions
Dobutamine, Milrinone, Normal Saline
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

In-vivo Efficacy Study of Patient Preoperative Preps

NCT01968356
View directory record Official record
Conditions
Skin Flora Bacterial Reduction Post-product Application
Interventions
3M CHG/IPA Prep Colorless, 3M CHG/IPA Prep Tint, ChloraPrep, Saline
Drug
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
49
States / cities
Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

NCT06592794
View directory record Official record
Conditions
Acute Gastroenteritis, Norovirus Acute Gastroenteritis
Interventions
mRNA-1403, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37,864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
184
States / cities
Birmingham, Alabama • Cullman, Alabama • Daphne, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819
View directory record Official record
Conditions
HIV-1-infection
Interventions
3BNC117-LS-J, 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2, Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3, Placebo
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma

NCT02749968
View directory record Official record
Conditions
Blunt Chest Wall Trauma, Rib Fracture, Sternal Fracture
Interventions
Liposomal bupivacaine, 0.9% sodium chloride
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cidofovir in Renal Transplant Recipients With BKVN

NCT00138424
View directory record Official record
Conditions
BK Virus (Nephropathy)
Interventions
Cidofovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 15, 2026, 1:21 AM EDT